cbdMD (NYSEAM:YCBD) Q1 2026 Earnings call February 17, 2026 04:20 PM ET Company ParticipantsBrad Whitford - Chief Accounting Officer, Treasurer, and SecretaryRonan Kennedy - CEO and CFOThomas McGovern - Equity Research AssociateOperatorGood afternoon. Welcome, ladies and gentlemen, to cbdMD, Inc.'s December 31st, 2025, First Fiscal Quarter of 2026 earnings call and update. This afternoon, the company issued a press release that provided an overview of its first quarter results, which followed the filing of ...

CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. ...

Core Viewpoint - cbdMD, Inc. will host a conference call on February 17, 2026, to discuss its financial results for the first quarter ending December 31, 2025, and business progress [1]. Company Overview - cbdMD, Inc. is a leading and highly trusted CBD company, recognized for its comprehensive line of U.S. produced THC-free CBD products and Farm Act compliant Delta 9 products [1]. - The company offers a range of brands, including Paw CBD for pet products, ATRx for functional mushroom products, and Herbal Oasis, a THC-infused social seltzer [1]. - Herbal Oasis is designed to provide a fast-acting, functional beverage that promotes clarity, balance, and joy, featuring an alcohol-free formula and wellness-forward ingredients [1]. Conference Call Details - The conference call is scheduled for February 17, 2026, at 4:20 p.m. Eastern Time, with a dial-in number for USA/Canada participants being 888-880-3330 [1]. - A webcast replay of the conference call will be available until February 17, 2027 [1].

Core Viewpoint - cbdMD, Inc. (YCBD) is demonstrating steady growth and improving financial health through strategic initiatives and disciplined cost management [1][2][5] Financial Performance - YCBD reported revenue of approximately $4.72 million for the period, slightly above the estimated $4.70 million, indicating steady growth [2][5] - The company has significantly reduced its operating loss to $2.1 million, an improvement from the $3.3 million loss in fiscal 2024, attributed to disciplined cost management and investments in quality and science [2][5] Financial Position - YCBD has strengthened its financial position through a $2.25 million Series C Preferred Stock private placement, with approximately $2.1 million available for working capital and strategic initiatives after expenses [3] - The Series C shares offer a 10% annual dividend and conversion options, providing flexibility for investors [3] - The company maintains a low debt-to-equity ratio of 0.16, indicating modest debt levels, and a current ratio of 1.56, suggesting good liquidity to cover short-term liabilities [4]

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported total net sales of $19.1 million, a slight decrease from $19.5 million in the prior year [16][20] - The operating loss for fiscal 2025 was approximately $2.1 million, improved from a loss of $3.3 million in 2024 [6][23] - Adjusted non-GAAP EBITDA improved from a loss of $1.7 million in 2024 to a loss of $900,000 in 2025 [6][25] - Gross profit margin for the fourth quarter of fiscal 2025 was 59%, up from 54% in the prior year [21] Business Line Data and Key Metrics Changes - E-commerce direct-to-consumer sales for the fourth quarter of fiscal 2025 were $3.5 million, a 6% year-over-year decrease [16][17] - The wholesale business generated $1.2 million in net sales for the fourth quarter of fiscal 2025, a 25% increase compared to $900,000 in the same quarter of fiscal 2024 [19][20] - For fiscal year 2025, the wholesale business generated net sales of $4.5 million, up from $3.8 million in 2024 [20] Market Data and Key Metrics Changes - Distribution for the new beverage brand, Oasis, has expanded to nine states, with improving case sell-through and growing distributor engagement [7][8] - E-commerce represented 77% of total net sales for fiscal year 2025, down from 81% in the prior year [17] Company Strategy and Development Direction - The company is focused on scaling the Oasis brand responsibly while driving efficient, profitable direct-to-consumer growth [29] - The strategy includes preserving margins and capital discipline while evaluating strategic opportunities aligned with regulatory strength [29] - The company aims to capitalize on the evolving regulatory environment, particularly with the recent executive order from the White House [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position in the evolving regulatory landscape, highlighting the potential for increased demand for CBD products [12][30] - The company believes that the heavy lifting of the turnaround is largely behind them, with fiscal 2026 focused on improving financial performance [30] - Management noted that the executive order could lead to significant demand for quality CBD products, particularly among Medicare consumers [46] Other Important Information - The company eliminated over $7 million in annual accrued preferred dividend obligations, significantly improving working capital [9][26] - The company has a strong liquidity position entering calendar 2026, with cash and cash equivalents of approximately $2.2 million [26][28] - The NYSE American confirmed that all prior compliance deficiencies had been resolved, reflecting progress in financial stability [11] Q&A Session Summary Question: What will be the key driver of growth in 2026? - Management believes there are growth opportunities in both the core cbdMD brand and the beverage side, with visibility on growth through November [35] Question: Can you explain the decline in direct-to-consumer business? - Management indicated that the decline is tied to organizational changes and is trending slightly up over prior year periods [36][37] Question: What is the timeline for Medicare coverage of CBD products? - Management mentioned that a pilot program is expected to start on April 1st, with potential for significant demand increase [39][40] Question: How will the executive order impact the business? - Management views the executive order as a potential game changer, with significant demand for CBD products expected in the coming years [45][46] Question: How are you prioritizing growth investments for fiscal 2026? - Management indicated that the next quarter will likely see more investment in the Oasis side, with ongoing evaluations based on regulatory developments [66]

Core Insights - cbdMD, Inc. reported its financial results for the fiscal year ending September 30, 2025, highlighting operational and financial improvements for the third consecutive year [1][2]. Financial Performance - The company experienced a loss from operations of $2.1 million, an improvement of $1.2 million from a $3.3 million loss in fiscal 2024 [3][12]. - Net sales for fiscal 2025 totaled $19.1 million, a slight decrease from $19.5 million in fiscal 2024 [12]. - Gross profit remained stable at 62% for both fiscal years 2025 and 2024 [12]. - The net loss attributable to common shareholders was approximately $4.3 million, or $0.51 per share, compared to a net loss of approximately $7.7 million, or $14.29 per share in fiscal 2024 [12][18]. Balance Sheet and Capital Structure - The net book value improved from under $2.0 million to approximately $7.2 million at year-end due to balance-sheet actions, including the conversion of Series A preferred equity [3][12]. - The company raised an additional $2.25 million in gross proceeds from the sale of Series C Convertible Preferred Stock to strengthen its balance sheet [3][12]. - As of September 30, 2025, the company had $2.3 million in cash and working capital of approximately $3.4 million, compared to $2.4 million in cash and negative $2.2 million in working capital at the same time in 2024 [12][18]. Business Developments - The Herbal Oasis brand expanded into Texas through a distribution partnership, establishing distribution in multiple states including North Carolina, Florida, Alabama, and Minnesota [6]. - The company emphasized its commitment to safety, quality, and scientific rigor in its operations, having invested millions in GMP manufacturing and compliance systems [4][5]. Regulatory Environment - cbdMD expressed optimism regarding the White House's executive order on cannabinoid decriminalization, which could lead to significant investments and support for the reimbursement of full-spectrum hemp for seniors [4][5]. - The company believes that increasing regulatory clarity will encourage additional research and institutional investment in the cannabinoid category [5].

Core Viewpoint - cbdMD, Inc. has entered into securities purchase agreements with institutional investors, issuing 1,000,000 shares of Series C Convertible Preferred Stock for gross proceeds of $2.25 million, aimed at supporting working capital and strategic initiatives [1][2]. Financial Details - The net proceeds from the issuance are approximately $2.1 million, which will be used for general corporate purposes and ongoing strategic initiatives [1]. - The Series C shares carry a 10% annual dividend and can be converted into common stock at an initial price of $2.25 per share, with anti-dilution protections [1]. Company Overview - cbdMD, Inc. is a leading wellness company that offers a range of U.S.-produced, hemp-derived cannabinoid products, including CBD, CBG, and CBN [4]. - The company emphasizes quality, innovation, and transparency, distributing products online and through retail partners across the United States [4].

As filed with the Securities and Exchange Commission on November 7, 2025 Registration No. 333-[●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 cbdMD, Inc. (Exact Name of Registrant As Specified In Its Charter) | North Carolina | 2833 | 47-3414576 | | --- | --- | --- | | (State Or Other Jurisdiction Of Incorporation Or Organization) | (Primary Standard Industrial | (I.R.S. Employer | | | Classification Code Number) | ...

Core Points - cbdMD, Inc. has completed a Series B Preferred Private Placement, raising $1.7 million from institutional investors [1][2] - The company plans to use the net proceeds of $1.5 million for working capital and general corporate purposes [1][2] - The Series B Convertible Preferred Stock issued has a 10% annual dividend and is convertible into common stock at an initial price of $1.00 per share [2] Financial Position - The CEO stated that the company ended the fiscal year with over $2.2 million in cash, indicating a strengthened balance sheet [2] - The financing is aimed at bolstering shareholder equity and supporting ongoing initiatives for distribution expansion and profitability [2] Company Overview - cbdMD, Inc. is a wellness company offering a range of hemp-derived cannabinoid products, including CBD, CBG, and CBN [4] - The company emphasizes quality, innovation, and transparency, distributing products online and through retail partners across the U.S. [4]

Core Insights - cbdMD, Inc. has launched a new topical product called Inferno Freeze, which is designed for athletes and fitness enthusiasts seeking advanced recovery solutions [1][2] - The product features cutting-edge nano-technology and a full-spectrum formula, aiming to provide rapid relief and enhanced performance [2][6] Product Highlights - Inferno Freeze contains 3000mg of CBD, 500mg of CBDa, and 50mg of THC, designed for intense relief [6] - The formulation includes 4% menthol, 3% camphor, and 0.04% capsaicin for rapid cooling and soothing effects [6] - The product is marketed as a high-strength, full-spectrum topical that combines cannabinoids with both cooling and heating botanicals [2][6] Company Overview - cbdMD, Inc. is recognized as a leading and trusted brand in the CBD industry, offering a wide range of THC-free products and other wellness solutions [4] - The company operates multiple brands, including Paw CBD for pet products and ATRx for functional mushroom products, as well as Herbal Oasis, a THC-infused beverage [4]